Akari Therapeutics, Plc APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Akari Therapeutics, Plc (AKTX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $711.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-13
- Akari Therapeutics, Plc apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $711.00K, a 1.11% decline year-over-year.
- Akari Therapeutics, Plc apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $305.00K, a 69.95% decline year-over-year.
- Akari Therapeutics, Plc apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $685.00K, a 176.21% increase year-over-year.
- Akari Therapeutics, Plc apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $719.00K, a 61.57% increase year-over-year.
- Akari Therapeutics, Plc apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $2.89M, a 28.73% increase from fiscal 2024.
- Akari Therapeutics, Plc apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $2.25M, a 95.22% increase from fiscal 2023.
- Akari Therapeutics, Plc apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $1.15M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $711.00K 10-Q · filed 2026-08-13 | $1.02M derived: sum of 2 quarters · filed 2026-08-13 | |||
| 2026-03-31 | $305.00K 10-Q · filed 2026-08-13 | ||||
| 2025-12-31 | $2.89M 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | $685.00K 10-Q · filed 2025-11-13 | $1.40M derived: sum of 2 quarters · filed 2026-08-13 | $2.42M derived: sum of 3 quarters · filed 2026-08-13 | ||
| 2025-06-30 | $719.00K 10-Q · filed 2026-08-13 | $1.73M derived: sum of 2 quarters · filed 2026-08-13 | |||
| 2025-03-31 | $1.01M 10-Q · filed 2026-08-13 | ||||
| 2024-12-31 | $2.25M 10-K · filed 2026-03-30 | ||||
| 2024-09-30 | $248.00K 10-Q · filed 2025-11-13 | $693.00K derived: sum of 2 quarters · filed 2025-11-13 | $989.00K derived: sum of 3 quarters · filed 2025-11-13 | ||
| 2024-06-30 | $445.00K 10-Q · filed 2025-11-13 | $741.00K derived: sum of 2 quarters · filed 2025-11-13 | |||
| 2024-03-31 | $296.00K 10-Q · filed 2025-11-13 | ||||
| 2023-12-31 | $1.15M 10-K · filed 2025-04-15 | ||||
| 2023-09-30 | $305.00K 10-Q · filed 2024-11-19 | $581.00K derived: sum of 2 quarters · filed 2024-11-19 | $846.00K derived: sum of 3 quarters · filed 2024-11-19 | ||
| 2023-06-30 | $276.00K 10-Q · filed 2024-11-19 | $541.53K 6-K · filed 2023-09-29 | |||
| 2023-03-31 | $265.00K 10-Q · filed 2024-11-19 | ||||
| 2022-12-31 | $452.05K 8-K · filed 2024-09-06 | $735.11K 20-F · filed 2023-05-01 | |||
| 2022-06-30 | $122.86K 6-K · filed 2022-09-27 | $221.69K 6-K · filed 2023-09-29 | |||
| 2022-03-31 | $98.84K 6-K · filed 2022-09-27 | ||||
| 2021-12-31 | $314.65K 20-F · filed 2023-05-01 | ||||
| 2021-06-30 | $82.10K 6-K · filed 2022-09-27 | $166.99K derived: sum of 2 quarters · filed 2022-09-27 | |||
| 2021-03-31 | $84.89K 6-K · filed 2022-09-27 | ||||
| 2020-12-31 | $325.52K 20-F · filed 2023-05-01 | ||||
| 2020-06-30 | $63.33K 6-K · filed 2021-09-22 | $163.83K derived: sum of 2 quarters · filed 2021-09-22 | |||
| 2020-03-31 | $100.50K 6-K · filed 2021-09-22 | ||||
| 2019-12-31 | $1.05M 20-F · filed 2022-05-16 | ||||
| 2019-06-30 | $409.62K 6-K · filed 2020-09-01 | $804.06K derived: sum of 2 quarters · filed 2020-09-01 | |||
| 2019-03-31 | $394.44K 6-K · filed 2020-09-01 | ||||
| 2018-12-31 | $1.65M 20-F · filed 2021-04-21 | ||||
| 2018-06-30 | $351.98K 6-K · filed 2019-08-29 | $827.94K 6-K · filed 2018-09-27 | |||
| 2018-03-31 | $475.96K 6-K · filed 2019-08-29 | ||||
| 2017-12-31 | $2.73M 20-F · filed 2019-04-23 | ||||
| 2017-06-30 | $1.75M 6-K · filed 2017-08-10 | ||||
| 2016-12-31 | $3.93M 20-F · filed 2019-04-23 | ||||
| 2016-06-30 | $805.41K derived: 6-K 6 month − 10-Q 3 month · filed 2017-04-14 | $1.62M 6-K · filed 2017-04-14 | |||
| 2016-03-31 | $816.80K 10-Q · filed 2016-05-12 | ||||
| 2015-12-31 | $1.04M 20-F · filed 2018-07-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |